Then, in 2011-2012, we had severe shortages of cancer drugs, to the point that oncologists had to decide who got them - and who didn't.
Big Pharma seems to be in flux today, as more drugs pass into generics and Big Pharma is looking for "most profitable" drugs - instead of "most helpful". Yet, there are some promising signs:
(May 2012) ASCO 2012: MOST PROMISING NEW CANCER DRUGS ARE ALL "TARGETED THERAPIES"
TEN PROMISING LATE STAGE CANCER DRUGS
SHRUNKEN TUMORS OF SEVEN DIFFERENT CANCERS FROM SINGLE ANTIBODY